Hot off the press- The U.S. Food and Drug Administration (FDA) has approved Sanofi-Aventis SA’s new
chemotherapy drug for advanced prostate cancer.
The drug, Jevtana (cabazitaxe) extended by nearly 2-1/2 months the lives of men with prostate
cancer tumors that resist standard treatment with hormones as well as chemotherapy.
The drug will be used after taxotere has failed.
Read more about this drug on my March 5, 2010 post, “On The Horizon – Cabazitaxel Extends Life After Chemotherapy Failure.”
Another break for men with advanced prostate cancer. Cabazitaxel, no longer “on the horizon”, it is now here today!
Joel T Nowak, MA, MSW